ERBB2 and breast cancer: Monoclonal antibodies to the HER2 receptor are used for first-line therapy of patients suffering from HER2/neu-positive subtypes of BC [109] However, about a year after the end of treatment, most patients become immune to the monoclonal antibody drug [110].